People · Operator
Named in public records as an officer, director or promoter · active 2025–2026 · Biotech / Pharma, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vinci Pharmaceuticals, Inc. | — | Biotech / Pharma | Series B | $21.2M | $76.8M | 2026 |
| Pleopharma, Inc. | — | Pharmaceuticals | Series A | $17.4M | $20.4M | 2025 |
Sarah Hassan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Sarah Hassan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Richard Lindstrom | 1 | 13 |
| Robert Finizio | 1 | 4 |
| Brij Sharma | 1 | 3 |
| Philip Gioia | 1 | 1 |
| Jay Constantine | 1 | 1 |
| Thomas F Poche | 1 | 1 |
| Daniel Alan Cartwright | 1 | 1 |
| Timothy F McInerney | 1 | 1 |
| Bisaro Paul | 1 | 1 |
| Thompson Tommy | 1 | 1 |
| Ginger Constantine | 1 | 1 |
| THOMAS POCHE | 1 | 1 |
| PAUL BISARO | 1 | 1 |
| DANIEL CARTWRITGHT | 1 | 1 |
| Sigurd Kirk | 1 | 1 |
| Neil Austrian Jr. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.